Target intelligence / Profile preview

PR domain zinc finger protein 8 (PRDM8)

Target
PRDM8
Molecular classification
Transcription factor, Chromatin regulator, Potential histone methyltransferase
01

Overview

PR domain zinc finger protein 8 (PRDM8) is a transcription factor of the PRDM protein family, characterized by a PR (PRDI-BF1 and RIZ1 homology) domain and multiple C2H2-type zinc finger motifs[2][3]. It is involved in the epigenetic regulation of gene expression by modulating chromatin structure, either through direct or indirect histone methylation[2]. PRDM8 plays a critical role in neuronal cell differentiation and survival in the retina and broader central nervous system, acting as an essential regulator of cell fate during development[1]. Mutations in PRDM8 are linked to neurological disorders, including developmental epileptic encephalopathies. The protein’s dual regulatory role—as either a transcriptional activator or repressor—is context-dependent, and dysregulation has been implicated in cancer and neurodevelopmental disorders[1][2]. PRDM8 is an emerging but not yet widely exploited therapeutic target, with the broader PRDM family subject to ongoing oncology drug discovery efforts.

Other names
PRDM8PR/SET domain 8PR domain-containing protein 8KMT8DPFM5EPM10PR domain 8PR domain zinc finger protein 8
02

Mechanism of action

Not applicable; no known therapeutic drugs directly target PRDM8, but inhibition of PR domain or zinc finger function is a theoretical approach[2].

03

Biological functions

Regulation of transcriptionControl of cell differentiation, especially neuronal developmentModulation of chromatin structureRegulation of cell fate and proliferation
04

Disease associations

CancerNeurological disorders, especially those involving retinal and neural developmentEpilepsy (Early infantile epileptic encephalopathy)
05

Safety considerations

Altered PRDM8 function contributes to abnormal neuronal differentiation and survival, particularly in the developing retina and central nervous system[1].Broad inhibition of PRDM proteins could disrupt normal development and homeostasis.
06

Biomarkers

Mutations in PRDM8 (KMT8D) are associated with early infantile epileptic encephalopathy (EIEE) and related developmental disorders; might be used as a genomic biomarker in rare epilepsy/neurodevelopmental syndromes.

Beyond the preview

Go deeper on PR domain zinc finger protein 8 (PRDM8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PR domain zinc finger protein 8 (PRDM8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call